Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — PharmAust — Shareholder Meeting (May 2015)
14 slides from Neurizon Therapeutics's shareholder meeting presentation, May 26, 2015
Slide 1: EGM Presentation May 26th 2015
EGM For personal use only Presentation May 26th 2015 ASX: PAA ACN 094 006 023 1
Slide 2: Disclaimer
DISCLAIMER • This presentation does not constitute investment advice. Neither this For personal use only presentation nor the information contained in it constitutes an offer, invitation , solicitation or recommendation in relation to the purchase or sale of shares. • Shareholders should not rely on
Slide 3: PharmAust Limited: Fast tracking leading edge technology in cancer therapy
PHARMAUST LIMITED …Fast tracking leading For personal use only edge technology in cancer therapy…. 3
Slide 4: Market
CANCER 1 Market For personal use only • Global cancer drug spending hits $100 billion in 2014- REF: IMS Health (includes supportive care drugs e.g. anti-emetics and treatments for anaemia) • Cancer market is seen rising to $117 billion to $147 billion in 2018, IMS forecast, a compound annual growth
Slide 5: Targets
CANCER 2 Targets For personal use only Medicines that target a specific protein or genetic mutation, as opposed to chemotherapies, now account for almost half of total U.S. cancer drug spending PPL-1 Targets mTOR, one of the most exciting recent cancer targets 5
Slide 6: Partnering
CANCER 3 Partnering For personal use only Oncology has become one of the major focus areas for pharmaceutical and biotechnology companies because of the high unmet need for improved treatments for multiple types of cancer PharmAust has a Research Option Agreement with a top 5 big Pharma for Veterina
Slide 7: Market Leaders
CANCER 4 Market Leaders For personal use only • Roche led the global cancer market with 2010 sales of $20.6bn, which was mainly based on sales from Avastin, Herceptin, MabThera, and Xeloda. • Novartis reported 2010 sales of $6bn, representing an increase of 14.4% over the previous year, which positi
Slide 8: The Drug Cocktail
CANCER 5 The Drug Cocktail For personal use only Most of the cancer drugs in development are likely to be used in combination with other marketed options, as scientists realize the importance of a multi-targeted approach in treating the disease. New cancer drugs, therefore, have to be judged not onl
Slide 9: PPL-1 in Advanced Cancer
PPL-1 IN ADVANCED CANCER For personal use only • Advanced Cancer is a term used to describe cancer that has spread and is unlikely to be cured. • Patients with advanced cancer have often failed “ta dard of Care a d have e o e multidrug resistant. • PharmAust is currently investigating PPL-1 in patie
Slide 10: Aim of Current Trial with PPL-1
AIM OF CURRENT TRIAL WITH PPL-1 For personal use only • To examine safety of PPL-1 and demonstrate the absence of adverse events • To identify a dose of PPL-1 that shows activity on the cancer • To demonstrate changes in tumour markers 10
Slide 11: Where Are We?
WHERE ARE WE? For personal use only • So far no material adverse events (7 patients treated with 3 completing 28-day course) • Completion of lowest dose cohort (dose 5mg/kg) – all patients responded to PPL-1 as measured by suppression of key cancer marker p70s6k. • Currently recruiting for next coho
Slide 12: What is the p70s6k Tumour Marker
WHAT IS THE p70s6k TUMOUR MARKER For personal use only 1. Overexpression of p70S6K in cancer patients is associated with aggressive disease and poor prognosis. 2. Recent studies showed that cancer patients with increased p70S6K phosphorylation had poor survival and increased metastasis 3. Reducing t
Slide 13: Conclusions
CONCLUSIONS For personal use only • PPL-1 APPEARS TO HAVE BROAD ANTICANCER ACTIVITY • PPL-1 SYNERGISES WITH CURRENT CANCER TREATMENTS • TUMOUR MARKER P70S6K SUPPRESSED IN ALL PATIENTS TESTED AT LOWEST DOSE OF PPL-1 TESTED 13
Slide 14: Questions
For personal use only THANK YOU QUESTIONS 14